PD864 - IMPACT OF DYSPHAGIA ON NUTRITIONAL STATUS IN PATIENTS UNDERGOING CONCURRENT CHEMORADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA

PD864

IMPACT OF DYSPHAGIA ON NUTRITIONAL STATUS IN PATIENTS UNDERGOING CONCURRENT CHEMORADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA

O. Alaoui Hichami¹, S. Taimi¹, Y. Rakii ¹, I. el moumni¹, T. kebdani ¹, K. Nouni¹, H. El kacemi¹, K. Hassouni¹, A. Lachgar¹, N. Benider^2,*

¹radiotherapy , national institut of oncology, ²National Institute of oncology, Rabat, Morocco

Rationale: Dysphagia is a frequent toxicity during chemoradiotherapy (CCRT) for nasopharyngeal carcinoma and may worsen nutritional status.This study aimed to evaluate the impact of dysphagia on nutritional deterioration.

Methods: We conducted a retrospective study over 12 months including 100 patients treated with CCRT. Dysphagia was graded using Common Terminology Criteria for Adverse Events(CTCAE v5.0).Nutritional status was assessed by weight loss, body mass index(BMI), and albumin. Patients were divided into dysphagia < grade 2 and ≥ grade 2.

Results: The median age was 48 years, with a male predominance (68%). At baseline, 32% of patients were already malnourished (BMI <18.5 or hypoalbuminemia). During treatment, dysphagia ≥ grade 2 was observed in 61% of patients, including 24% with grade 3.

Patients with dysphagia ≥ grade 2 experienced significantly higher weight loss compared to those with mild or no dysphagia (mean weight loss: 9.2% vs 4.1%). Severe weight loss (≥10%) occurred in 38% of patients with dysphagia ≥ grade 2 versus 12% in the other group. Nutritional support was required in 57% vs 21% . Treatment interruptions were more frequent in patients with severe dysphagia (19% vs 6%).

A significant correlation was found between dysphagia and weight loss and hypoalbuminemia at the end of treatment was more frequent in patients with severe dysphagia (46% vs 18%).

Conclusion: Dysphagia significantly impacts nutritional status during CCRT for nasopharyngeal carcinoma. Early nutritional management is essential to improve treatment tolerance

Disclosure of Interest: None declared